BioNTech's Covid Vaccine Revenue Forecast Slashed Amid Pandemic Decline
TL;DR Summary
Bloomberg's website is displaying a message asking users to ensure their browser supports JavaScript and cookies, and that they are not blocking them from loading. Users are directed to contact the support team for assistance.
- BioNTech Slashes Covid Vaccine Forecast as Pandemic Fades Bloomberg
- BioNTech cuts 2023 revenue target on reduced prospects for vaccine Yahoo Finance
- BioNTech Gets a Shot in the Arm After Earnings: Is It Sustainable? RealMoney
- BioNTech cuts revenue forecast on lower demand for Covid jabs Financial Times
- BioNTech slashes 2023 revenue projection from €5B to €4B FiercePharma
- View Full Coverage on Google News
Reading Insights
Total Reads
0
Unique Readers
9
Time Saved
0 min
vs 1 min read
Condensed
39%
57 → 35 words
Want the full story? Read the original article
Read on Bloomberg